Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States

Russell A. Settipane, James L. Kreindler, Yen Chung, +1

Annals of Allergy Asthma & Immunology

<p>Patient and physician preferences for attributes of biologic medications for severe asthma</p>

Heather L. Gelhorn, Zaneta Balantac, Christopher S. Ambrose, +2

Patient Preference and Adherence

Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma

Trung N. Tran, Sharon MacLachlan, Wesley L. Hicks, +5

The Journal of Allergy and Clinical Immunology In Practice

Clinical and economic burden of severe asthma among US patients treated with biologic therapies

Joan Reibman, Laren Tan, Chris Ambrose, +5

Annals of Allergy Asthma & Immunology

Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma

Robert S. Zeiger, Patrick W. Sullivan, Yen Chung, +3

The Journal of Allergy and Clinical Immunology In Practice

AsthmaAllergyAllergic RhinitisPersistent AsthmaMedicine +1

Real-world effectiveness of benralizumab: Results from the ZEPHYR 1 Study

Yen Chung, Rohit Katial, Fan Mu, +5

Annals of Allergy Asthma & Immunology

<p>Blood Eosinophil Count and Hospital Readmission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease</p>

Matthew Hegewald, Benjamin D. Horne, Frank Trudo, +4

International Journal of COPD

Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma

J.F. Most, Christopher S. Ambrose, Yen Chung, +6

The Journal of Allergy and Clinical Immunology In Practice

Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2

Donna Carstens, Diego J. Maselli, Mu Fan, +6

The Journal of Allergy and Clinical Immunology In Practice

Incremental cost burden among patients with severe uncontrolled asthma in the United States

Autumn Burnette, Yan Wang, Pallavi Rane, +6

Journal of Managed Care & Specialty Pharmacy